Ace the CARN Challenge 2025 – Empower Your Nursing Passion!

Chlorpromazine is classified as an alpha-adrenergic blocking agent in cases of overdose due to its pharmacological properties. As a typical antipsychotic medication, chlorpromazine primarily acts as a dopamine receptor antagonist. However, it also exhibits significant antagonist activity at alpha-adrenergic receptors. In the context of overdose, the alpha-adrenergic blocking effects can lead to hypotension and sedation, which are critical considerations for managing an overdose situation.

The presence of antagonist activity at these receptors means that high doses of chlorpromazine can lead to vasodilation and decreased vascular resistance, contributing to low blood pressure. Recognizing chlorpromazine's role in blocking these adrenergic receptors helps healthcare providers anticipate and mitigate potential cardiovascular side effects during overdose management. This understanding is essential for effective treatment and stabilization of patients experiencing an adverse reaction to the drug.

In contrast, other classifications such as beta-adrenergic, dopaminergic, or sodium channel blockers do not accurately characterize chlorpromazine's primary actions or the consequences of overdose. These classifications would imply different mechanisms and therapeutic implications that do not align with the established effects of chlorpromazine.